Literature DB >> 6637914

Trivalent, inactivated influenza virus vaccine in children with sickle cell disease.

W P Glezen, L S Glezen, R Alcorn.   

Abstract

School-aged children with sickle cell disease who were administered a single dose of trivalent, inactivated influenza virus vaccine had serum antibody titers comparable to titers achieved in the two-dose trials carried out in 1978. The proportion exhibiting titers of 1:32 or greater ranged from 84% to 68% for the three antigens. Preschool children with sickle cell disease received two doses of the same vaccine four weeks apart and their postimmunization titers to each of the antigens were slightly lower. The vaccine, which contained 15 micrograms of hemagglutinin to each of three influenza viruses, A (H1N1), A (H3N2), and B, in a volume of 0.5 mL, was adequately immunogenic for schoolchildren who probably had been primed by previous natural infection. Younger children who received the same quantity in two divided doses four weeks apart had slightly lower but acceptable titers and tolerated the injections with few side reactions.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6637914     DOI: 10.1001/archpedi.1983.02140370055018

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  8 in total

Review 1.  Vaccination of adolescents with chronic medical conditions: Special considerations and strategies for enhancing uptake.

Authors:  Annika M Hofstetter; Philip LaRussa; Susan L Rosenthal
Journal:  Hum Vaccin Immunother       Date:  2015-07-25       Impact factor: 3.452

2.  Severe pandemic H1N1 and seasonal influenza in children and young adults with sickle cell disease.

Authors:  John J Strouse; Megan E Reller; David G Bundy; Martha Amoako; Maria Cancio; Rachel N Han; Alexandra Valsamakis; James F Casella
Journal:  Blood       Date:  2010-07-23       Impact factor: 22.113

3.  Humoral and cell-mediated immune responses to monovalent 2009 influenza A/H1N1 and seasonal trivalent influenza vaccines in high-risk children.

Authors:  Caroline B Long; Irene Ramos; Deepa Rastogi; Deepa Manwani; Ginger Janow; Marcela Del Rio; Marguerite Mayers; Betsy C Herold; Ana Fernandez-Sesma; Rebecca Pellett Madan
Journal:  J Pediatr       Date:  2011-08-15       Impact factor: 4.406

4.  Pneumonia in young children with homozygous sickle cell disease: risk and clinical features.

Authors:  K De Ceulaer; K W McMullen; G H Maude; R Keatinge; G R Serjeant
Journal:  Eur J Pediatr       Date:  1985-09       Impact factor: 3.183

5.  Influenza vaccine effectiveness and disease burden in children and adolescents with sickle cell disease: 2012-2017.

Authors:  Carol M Kao; Kristina Lai; John M McAteer; Mohnd Elmontser; Elizabeth M Quincer; Marianne E M Yee; Ashley Tippet; Robert C Jerris; Peter A Lane; Evan J Anderson; Nitya Bakshi; Inci Yildirim
Journal:  Pediatr Blood Cancer       Date:  2020-05-29       Impact factor: 3.167

6.  Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children.

Authors:  Karen L Kotloff; Natasha B Halasa; Christopher J Harrison; Janet A Englund; Emmanuel B Walter; James C King; C Buddy Creech; Sara A Healy; Rowena J Dolor; Ina Stephens; Kathryn M Edwards; Diana L Noah; Heather Hill; Mark Wolff
Journal:  Pediatr Infect Dis J       Date:  2014-08       Impact factor: 2.129

7.  Burden of influenza-related hospitalizations among children with sickle cell disease.

Authors:  David G Bundy; John J Strouse; James F Casella; Marlene R Miller
Journal:  Pediatrics       Date:  2010-01-25       Impact factor: 7.124

Review 8.  Potential Impact of Co-Infections and Co-Morbidities Prevalent in Africa on Influenza Severity and Frequency: A Systematic Review.

Authors:  Adam L Cohen; Meredith McMorrow; Sibongile Walaza; Cheryl Cohen; Stefano Tempia; Marissa Alexander-Scott; Marc-Alain Widdowson
Journal:  PLoS One       Date:  2015-06-11       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.